Metastatic Colorectal Cancer Clinical Trials

81 recruiting

Metastatic Colorectal Cancer Trials at a Glance

113 actively recruiting trials for metastatic colorectal cancer are listed on ClinicalTrialsFinder across 6 cities in 46 countries. The largest study group is Phase 2 with 66 trials, with the heaviest enrollment activity in Houston, Paris, and Barcelona. Lead sponsors running metastatic colorectal cancer studies include Fudan University, M.D. Anderson Cancer Center, and National Cancer Institute (NCI).

Browse metastatic colorectal cancer trials by phase

Treatments under study

About Metastatic Colorectal Cancer Clinical Trials

Looking for clinical trials for Metastatic Colorectal Cancer? There are currently 81 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Colorectal Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Colorectal Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 113 trials

Recruiting
Phase 1Phase 2

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer
National Cancer Institute (NCI)60 enrolled1 locationNCT06149481
Recruiting
Phase 2

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Metastatic Breast CarcinomaMetastatic Ovarian CancerMetastatic Pancreatic Cancer+2 more
National Cancer Institute (NCI)332 enrolled1 locationNCT01174121
Recruiting
Phase 2

New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
The First Hospital of Jilin University30 enrolled1 locationNCT07559760
Recruiting
Phase 1

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Metastatic Colorectal Cancer
Hoffmann-La Roche542 enrolled76 locationsNCT04929223
Recruiting
Phase 3

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Metastatic Colorectal Cancer
Amgen450 enrolled286 locationsNCT06252649
Recruiting
Phase 2

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

Ras-mutated Metastatic Colorectal Cancer
Oncolytics Biotech60 enrolled1 locationNCT07446322
Recruiting
Phase 2

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Metastatic Colorectal Cancer
AstraZeneca120 enrolled76 locationsNCT06792695
Recruiting
Phase 3

A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
Taizhou Hanzhong biomedical co. LTD190 enrolled63 locationsNCT05652894
Recruiting
Phase 1Phase 2

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

Metastatic Colorectal Cancer
BioNTech SE482 enrolled14 locationsNCT07079631
Recruiting

Assessing the Efficacy and Safety of ctDNA-driven Selection for Anti-EGFR Retreatment in a Real World Metastatic Colorectal Cancer Patients Cohort (the REalCHALLENGE Study)

Metastatic Colorectal Cancer (CRC)
Niguarda Hospital250 enrolled1 locationNCT07536113
Recruiting
Phase 1

A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI

Metastatic Colorectal Cancer
R-Pharm180 enrolled26 locationsNCT07543744
Recruiting
Phase 2

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
AbbVie390 enrolled44 locationsNCT06820463
Recruiting
Phase 1Phase 2

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

Advanced or Metastatic Colorectal Cancer
Janssen Research & Development, LLC225 enrolled53 locationsNCT05379595
Recruiting
Phase 1

A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer
Hoffmann-La Roche180 enrolled1 locationNCT07416552
Recruiting
Phase 2

Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (CRC)
The Methodist Hospital Research Institute50 enrolled1 locationNCT07042685
Recruiting
Phase 1

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Metastatic Breast CancerAdvanced Breast CancerMetastatic Lung Cancer+6 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)392 enrolled36 locationsNCT06625775
Recruiting
Phase 3

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (CRC)
Summit Therapeutics600 enrolled54 locationsNCT07228832
Recruiting
Phase 2

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

Hepatocellular CarcinomaMetastatic Colorectal Cancer
H. Lee Moffitt Cancer Center and Research Institute40 enrolled1 locationNCT06553885
Recruiting
Phase 2Phase 3

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb990 enrolled263 locationsNCT07221357
Recruiting
Phase 2

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
University of Wisconsin, Madison50 enrolled1 locationNCT05854498